WASHINGTON--(BUSINESS WIRE)--Liquidity Services (NASDAQ: LQDT), a global solution provider in the reverse supply chain with the world’s largest marketplace for business surplus, is pleased to highlight four sales of biopharmaceutical assets located in Singapore, the U.K. and the U.S. Information about the sales can be found on GoIndustry DoveBid (www.go-dove.com), a Liquidity Services marketplace where more than $450 million of biopharmaceutical assets from small, medium-size and Fortune 1,000 companies have been sold to a global audience of registered industry buyers.
Featured sales include:
BioPharma #501460 starts at 12 a.m. EST on November 7, 2016 and closes at 5 p.m. EST on November 9, 2016. The event features more than 240 assets from a Fortune 100 global pharmaceutical company’s facilities in California, Illinois, New Jersey, North Carolina and Ohio, including a Beckman Optima TL benchtop ultracentrifuge and multiple ThermoFisher Scientific Forma™ environmental chambers.
BioPharma #501461, a 3-day event that is part of GoIndustry DoveBid’s regular monthly North American BioPharma Equipment Market. The sale, which opens November 14, 2016 at 12 a.m. EST and closes at 5 p.m. EST on November 16, 2016, features more than 30 assets located at two U.S. facilities of top global pharmaceutical manufacturers. Specific items up for bid include a PerkinElmer Optima 7000 DV optical emission spectrometer and an Applied Biosystems 9800 fast thermal cycler.
BioPharma #501213 is a private treaty sale for packaging equipment from a specialty pharmaceutical company. The assets, which include a Bergami AS 150 intermittent motion horizontal cartoner and a Longford M350 friction feeder, are located at the company’s facility in Miami, FL. The sale closes at 5 p.m. EST on December 30, 2016.
BioPharma #671058 is a private treaty sale for a 2012 Rousselet Robatel ENBL1663S horizontal centrifuge used for solid/liquid separation from a manufacturing facility of a Fortune 500 global life sciences company located in Singapore. The sale closes at 3 a.m. EST on December 30, 2016.
“Globalization is creating new growth markets around the world,” said Gardner Dudley, president of Liquidity Services’ Capital Assets Group. “For biopharmaceutical companies, this means expanding operations to serve a burgeoning customer base. With nearly three million buyers in almost 200 countries and territories, Liquidity Services understands the impact of expansion and helps companies leverage the power of their complex, global surplus programs, providing the right support when and where needed.”